methyl 4-iodobicyclo[2.2.2]octane-1-carboxylate | 94994-00-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: methyl 4-iodobicyclo[2.2.2]octane-1-carboxylate
• 英文别名: methyl 4-iodobicyclo<2.2.2>octane-1-carboxylate；Methyl 4-iodobicyclo[2.2.2]octane-1-carboxylate
• CAS: 94994-00-0
• 化学式: C₁₀H₁₅IO₂
• 分子量: 294.132
• InChiKey: SXCLQFMOKUHRIA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险性防范说明：
  P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P305+P351+P338,P330,P332+P313,P337+P313,P362,P403+P233,P405,P501
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  methyl 4-iodobicyclo[2.2.2]octane-1-carboxylate 在 氢氧化钾 、 dimethyl sulfide borane 、 一氯化碘 作用下， 以 四氢呋喃 、 四氯化碳 、 乙醇 为溶剂， 反应 48.0h， 生成 4-chlorobicyclo<2.2.2>octane-1-methanol
  参考文献：
  名称：

  Polar substituent effects on fluorine-19 chemical shifts of aryl and vinyl fluorides: a fluorine-19 nuclear magnetic resonance study of some 1,1-difluoro-2-(4-substituted-bicyclo[2.2.2]oct-1-yl)ethenes

  摘要：

  DOI：

  10.1021/jo00207a033
• 作为产物：
  描述：

  4-(甲氧羰基)双环[2.2.2]辛烷-1-羧酸 在 4-二甲氨基吡啶 、 四丁基碘化铵 、 N,N'-二环己基碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 生成 methyl 4-iodobicyclo[2.2.2]octane-1-carboxylate
  参考文献：
  名称：

  光诱导无金属脱羧转化：快速获取胺、烷基卤化物和烯烃

  摘要：

  在此，我们描述了一种多功能的光催化策略，用于在n Bu 4 NI 存在下一步将氧化还原活性酯 (RAE) 脱羧转化为各种卤代烷、胺和烯烃。它是一种直接的方法，适用于一系列伯、仲、叔脂肪族羧酸衍生物和复杂天然产物的功能化。从机制上讲，电荷转移复合物 (CTC) 是通过 RAE 和n Bu 4之间的非共价相互作用形成的你。在光激发后，氨盐充当有效的电子供体和自由基重组的碘源。温和的反应条件使该方法可用于复杂天然产物的修饰和多功能的后续转化。

  DOI：

  10.1002/ejoc.202300167

文献信息

• Triphenylphosphine-Catalyzed Alkylative Iododecarboxylation with Lithium Iodide under Visible Light
  作者：Ming-Chen Fu、Jia-Xin Wang、Rui Shang

  DOI：10.1021/acs.orglett.0c03173

  日期：2020.11.6

  light-emitting diodes, PPh3 catalyzes the iododecarboxylation of aliphatic carboxylic acid derived N-(acyloxy)phthalimide with lithium iodide as an iodine source. The reaction delivers primary, secondary, and bridgehead tertiary alkyl iodides in acetone solvent, and the alkyl iodide products were easily used to generate C–N, C–O, C–F, and C–S bonds to allow various decarboxylative transformations without

  在456 nm蓝色发光二极管的照射下，PPh 3用碘化锂作为碘源催化脂肪族羧酸衍生的N-（酰氧基）邻苯二甲酰亚胺的碘脱羧。该反应在丙酮溶剂中提供伯，仲和桥头叔烷基碘化物，该烷基碘化物产物易于用于生成C–N，C–O，C–F和C–S键，从而无需使用各种脱羧转化即可过渡金属或有机染料基光催化剂。
• BRIDGED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20190127358A1

  公开（公告）日：2019-05-02

  The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds modulate the activity of farnesoid X receptor (FXR), for example, as agonists. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

  本发明提供了式（I）的化合物： 或其立体异构体、互变异构体或药学上可接受的盐或溶剂，其中所有变量如本文所定义。这些化合物调节法尼索尔X受体（FXR）的活性，例如作为激动剂。本发明还涉及包括这些化合物的药物组合物以及利用这些化合物和药物组合物治疗与FXR失调相关的疾病、紊乱或病况的方法，例如病理性纤维化、移植排斥、癌症、骨质疏松症和炎症性疾病。
• Bridged bicyclic compounds as farnesoid X receptor modulators
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US10730863B2

  公开（公告）日：2020-08-04

  The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds modulate the activity of farnesoid X receptor (FXR), for example, as agonists. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

  本发明提供了式 (I) 的化合物： 或其立体异构体、同系物或药学上可接受的盐或溶液，其中所有变量均如本文所定义。这些化合物可调节法尼类固醇 X 受体（FXR）的活性，例如作为激动剂。本发明还涉及包含这些化合物的药物组合物，以及通过使用这些化合物和药物组合物治疗与 FXR 失调相关的疾病、紊乱或病症的方法，如病理性纤维化、移植排斥、癌症、骨质疏松症和炎症性疾病。
• Synthesis of bridgehead fluorides by fluorodeiodination
  作者：Ernest W. Della、Nicholas J. Head

  DOI：10.1021/jo00036a018

  日期：1992.5

  Fluorodeiodination is found to be an attractive procedure for the synthesis of bridgehead fluorides. Thus, treatment of the corresponding iodide with xenon difluoride in dichloromethane at ambient temperature generally leads to high yields of the fluoride. Evidence suggests the intermediacy of the bridgehead cation in this reaction, and accordingly the substrates which are unfavorably disposed to fluorodeiodination are the bicyclo[n.1.1]alkyl iodides. In this context the isolation of a small quantity of methyl 4-fluorobicyclo[2.1.1]hexane-1-carboxylate (46, R = COOMe) is significant because it represents the first occasion on which the elusive 1-bicyclo[2.1.1]hexyl cation has been trapped. We have also demonstrated that synthesis of the iodides themselves can be accomplished efficiently both by Barton halodecarboxylation and by treatment of the carboxylic acid with lead tetraacetate and iodine.
• Adcock, William; Gangodawila, Hemakanthi; Kok, Gaik B., Organometallics, 1987, vol. 6, # 1, p. 156 - 166
  作者：Adcock, William、Gangodawila, Hemakanthi、Kok, Gaik B.、Iyer, V. Sankar、Kitching, William、Drew, Gregory M.、Young, David

  DOI：——

  日期：——